← Leaderboards
Eric Padron
H. Lee Moffitt Cancer Ctr & Res Inst
$5,554,159
Attributed
$5,554,159
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,554,159 · 3
By mechanism
R37$3,422,767 · 1
R01$1,725,494 · 1
R21$405,898 · 1
Top collaborators
No co-investigators on record.
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Alvaro N Monteiro$2,690,824
- Sion Llewelyn Williams$1,821,557
- Wayne Guida$1,581,602
- Marie Catherine Lee$406,943
Others in their field
Other Emerging Leaders on “Monocytosis”
- Cameron Stuart McAlpine · Massachusetts General Hospital$3,453,002
- Norifumi Urao · University Of Illinois At Chicago$1,611,755
- Peng Zhao · University Of California, San Diego$1,060,848
- Jose Orlando Aleman · New York University School Of Medicine$823,193
- Eric J Allenspach · Seattle Children'S Hospital$809,880
- Mauricio D Dorfman · University Of Washington$648,000
Research focus
MonocytosisSamplingChronic Myelomonocytic LeukemiaLeukemiaChronicCytopeniaNatural HistoryPre-ClinicalAcute Myelocytic LeukemiaMyeloproliferative DiseaseDysplasiaGene MutationResponseProspectiveImmunocompromised HostCytokinePhenotypeGenetic TranscriptionCredentialingMouse ModelMutationJak1 GeneBindingGenetic
Grant awards (12)
The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia$522,013
R01 · FY2025 · CA · contact PI
Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia$477,698
R37 · FY2025 · CA · contact PI
The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia$567,382
R01 · FY2024 · CA · contact PI
Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia$453,813
R37 · FY2024 · CA · contact PI
The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia$636,099
R01 · FY2023 · CA · contact PI
Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia$486,704
R37 · FY2023 · CA · contact PI
Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia$496,638
R37 · FY2022 · CA · contact PI
Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia$496,638
R37 · FY2021 · CA · contact PI
Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia$496,640
R37 · FY2020 · CA · contact PI
Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia$514,636
R37 · FY2019 · CA · contact PI
MALAT1 Depletion as a Therapeutic Strategy in Chronic Myelomonocytic Leukemia (CMML)$181,438
R21 · FY2019 · CA · contact PI
MALAT1 Depletion as a Therapeutic Strategy in Chronic Myelomonocytic Leukemia (CMML)$224,460
R21 · FY2018 · CA · contact PI